IL286914A - Systemic antiparasitic agents of the isoxazoline type for the treatment or prevention of viral or vector-borne diseases - Google Patents
Systemic antiparasitic agents of the isoxazoline type for the treatment or prevention of viral or vector-borne diseasesInfo
- Publication number
- IL286914A IL286914A IL286914A IL28691421A IL286914A IL 286914 A IL286914 A IL 286914A IL 286914 A IL286914 A IL 286914A IL 28691421 A IL28691421 A IL 28691421A IL 286914 A IL286914 A IL 286914A
- Authority
- IL
- Israel
- Prior art keywords
- prophylaxis
- borne
- systemic
- vector
- disease treatment
- Prior art date
Links
- WEQPBCSPRXFQQS-UHFFFAOYSA-N 4,5-dihydro-1,2-oxazole Chemical compound C1CC=NO1 WEQPBCSPRXFQQS-UHFFFAOYSA-N 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 230000000590 parasiticidal effect Effects 0.000 title 1
- 239000002297 parasiticide Substances 0.000 title 1
- 238000011321 prophylaxis Methods 0.000 title 1
- 230000009885 systemic effect Effects 0.000 title 1
- 238000011282 treatment Methods 0.000 title 1
- 230000003612 virological effect Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962829573P | 2019-04-04 | 2019-04-04 | |
| PCT/IB2020/053229 WO2020202111A1 (en) | 2019-04-04 | 2020-04-03 | Systemic isoxazoline parasiticides for vector-borne and viral disease treatment or prophylaxis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL286914A true IL286914A (en) | 2021-10-31 |
Family
ID=72667108
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL286914A IL286914A (en) | 2019-04-04 | 2021-10-03 | Systemic antiparasitic agents of the isoxazoline type for the treatment or prevention of viral or vector-borne diseases |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20220160682A1 (https=) |
| EP (1) | EP3946325A4 (https=) |
| JP (1) | JP2022527359A (https=) |
| KR (1) | KR20220054241A (https=) |
| CN (1) | CN113993518A (https=) |
| AU (1) | AU2020251960A1 (https=) |
| BR (1) | BR112021019931A2 (https=) |
| CA (1) | CA3136042A1 (https=) |
| IL (1) | IL286914A (https=) |
| MX (1) | MX2021012188A (https=) |
| WO (1) | WO2020202111A1 (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20170232024A1 (en) | 2014-08-04 | 2017-08-17 | Jerry Tan Eye Surgery Pte Ltd | Pharmaceutical compositions for demodex related blepharitis and eyelid crusting |
| WO2019118928A1 (en) | 2017-12-15 | 2019-06-20 | Tarsus Pharmaceuticals, Inc. | Isoxazoline parasiticide formulations and methods for treating blepharitis |
| US12502377B2 (en) | 2019-04-04 | 2025-12-23 | Tarsus Pharmaceuticals, Inc. | Method of eradicating ticks that attach to humans using lotilaner formulations |
| CN111265528A (zh) | 2020-01-21 | 2020-06-12 | 中国人民解放军军事科学院军事医学研究院 | 法匹拉韦在治疗冠状病毒感染方面的应用 |
| WO2022079496A1 (en) * | 2020-10-13 | 2022-04-21 | Menschlich Healthcare Opc Private Limited | A pharmaceutical composition of nitazoxanide, albendazole and pyrantel and method thereof |
| CN112294793B (zh) * | 2020-10-21 | 2022-03-22 | 青岛海洋生物医药研究院股份有限公司 | 氯生太尔或其药学上可接受的盐在制备用于预防和/或治疗冠状病毒感染的药物中的应用 |
| WO2022130031A1 (en) * | 2020-12-17 | 2022-06-23 | Chander Mohan Negi | A pharmaceutical composition of nitazoxanide and mefloquine and method thereof |
| CN118420621A (zh) * | 2021-02-07 | 2024-08-02 | 南京知和医药科技有限公司 | 一种磺酰胺类多环化合物及其制备方法与用途 |
| CN119212555A (zh) * | 2022-05-16 | 2024-12-27 | 先正达农作物保护股份公司 | 蚊控制方法 |
| WO2024168149A1 (en) * | 2023-02-10 | 2024-08-15 | Tarsus Pharmaceuticals, Inc. | Isoxazoline parasiticide formulations and methods for treating blepharitis |
| US11903962B1 (en) * | 2023-05-07 | 2024-02-20 | Michael Farber | Isoxazoline complexes and compositions thereof |
| US20240366572A1 (en) * | 2023-05-07 | 2024-11-07 | Michael Farber | Isoxazoline complexes and compositions thereof |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI556741B (zh) * | 2007-08-17 | 2016-11-11 | 英特威特國際股份有限公司 | 異唑啉組成物及其作為抗寄生蟲藥上的應用 |
| US8313752B2 (en) * | 2009-04-14 | 2012-11-20 | Merial Limited | Macrocyclic lactone combination compositions, vaccines and methods for producing same |
| JP2020503369A (ja) * | 2016-10-31 | 2020-01-30 | ザ・スクリップス・リサーチ・インスティテュート | 媒介体由来疾患伝染を予防する方法と組成物 |
| PL3846786T3 (pl) * | 2018-09-05 | 2025-03-03 | Zoetis Services Llc | Smaczne formulacje przeciwpasożytnicze |
| BR112022000982A2 (pt) * | 2019-07-22 | 2022-03-08 | Intervet Int Bv | Forma de dosagem veterinária mastigável macia |
-
2020
- 2020-04-03 EP EP20784367.3A patent/EP3946325A4/en active Pending
- 2020-04-03 WO PCT/IB2020/053229 patent/WO2020202111A1/en not_active Ceased
- 2020-04-03 JP JP2021559187A patent/JP2022527359A/ja active Pending
- 2020-04-03 MX MX2021012188A patent/MX2021012188A/es unknown
- 2020-04-03 AU AU2020251960A patent/AU2020251960A1/en active Pending
- 2020-04-03 US US17/594,144 patent/US20220160682A1/en not_active Abandoned
- 2020-04-03 KR KR1020217036211A patent/KR20220054241A/ko active Pending
- 2020-04-03 CN CN202080041597.8A patent/CN113993518A/zh active Pending
- 2020-04-03 BR BR112021019931A patent/BR112021019931A2/pt unknown
- 2020-04-03 CA CA3136042A patent/CA3136042A1/en active Pending
-
2021
- 2021-10-03 IL IL286914A patent/IL286914A/en unknown
-
2023
- 2023-03-15 US US18/184,513 patent/US20230218584A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP3946325A1 (en) | 2022-02-09 |
| US20220160682A1 (en) | 2022-05-26 |
| MX2021012188A (es) | 2022-02-11 |
| EP3946325A4 (en) | 2022-12-21 |
| KR20220054241A (ko) | 2022-05-02 |
| CA3136042A1 (en) | 2020-10-08 |
| US20230218584A1 (en) | 2023-07-13 |
| BR112021019931A2 (pt) | 2021-12-07 |
| WO2020202111A1 (en) | 2020-10-08 |
| AU2020251960A1 (en) | 2021-11-11 |
| JP2022527359A (ja) | 2022-06-01 |
| CN113993518A (zh) | 2022-01-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL286914A (en) | Systemic antiparasitic agents of the isoxazoline type for the treatment or prevention of viral or vector-borne diseases | |
| IL281277A (en) | Preparations and methods for treating viral infections | |
| IL290792B1 (en) | Preparations and methods for treating viral infections | |
| ZA202002069B (en) | Novel mek-inhibitor for the treatment of viral and bacterial infections | |
| SG11202000939PA (en) | Cytokine conjugates for the treatment of proliferative and infectious diseases | |
| SG11202104663PA (en) | Treatment of nsclc patients refractory for anti-pd-1 antibody | |
| IL283938A (en) | Compounds and their use in the treatment of a1-antitrypsin deficiency | |
| ZA202202370B (en) | Compositions and methods for treating viral infections | |
| IL273162B (en) | Preparations containing oleandrin for the treatment of viral infection | |
| IL289109A (en) | Isoxazoline formulations against parasites and methods for treating blepharitis | |
| GB202317063D0 (en) | Microfluidic proximal tubile kidney-on-chip | |
| IL284099A (en) | Adeno-associated viruses and their uses for inner ear therapy | |
| GB201819164D0 (en) | Artificial-intelligence-assisted surgery | |
| SMT202500382T1 (it) | Composizioni per trattare e/o prevenire malattie da aggregazione proteica | |
| EP4007581A4 (en) | PROTOCOLS AND DOSAGE REGIMENS FOR AMINOSTEROL TREATMENT | |
| GB201803197D0 (en) | Viral treatment | |
| EP3634583A4 (en) | LONG-LASTING EFFECT IMPLANT FOR THE TREATMENT OF INFECTIOUS DISEASES | |
| GB201907493D0 (en) | Agents and methods for treating viral infections | |
| CY1126747T1 (el) | Φαρμακο για την αγωγη λοιμωδων νοσηματων | |
| IL289692A (en) | A device for treating vaginal atrophy | |
| EP3650015A4 (en) | COMBINED DRUG PREPARATION FOR THERAPY OF VIRAL INFECTIONS | |
| HUE045242T2 (hu) | Vírusfertõzések megelõzésére és terápiájára szánt ágens | |
| GB201911728D0 (en) | Bacterial composistions for the treatment of disease | |
| SG10202010317VA (en) | Pyrimidine prodrugs for the treatment of viral infections and further diseases | |
| GB202315114D0 (en) | Viral treatment |